Bill Niland CEO at ReGelTec Testimonial
ReGelTec, a U.S.-based company specializing in degenerative disc disease, is gearing up to launch an early feasibility trial for its innovative injectable polymer in Barranquilla, Colombia. Scheduled to begin in late April or early May 2020, the trial highlights the advantages of conducting studies outside the United States, including faster timelines and reduced costs.
CEO Bill Niland, who has extensive experience managing clinical trials in Europe, chose Colombia for its high-quality hospitals, skilled surgeons, and experienced investigators. His collaboration with bioaccess® has been a pivotal part of the process. Niland first connected with bioaccess® six years ago through LinkedIn during a previous venture. When the time came to set up this trial, he reestablished the partnership, relying on their expertise to navigate the regulatory and logistical challenges.
Niland has praised the professionalism and efficiency of the bioaccess® team, particularly Monica and Julio, who played key roles in getting the trial approved and operational. Reflecting on his experience, he recommends bioaccess® to any medical device company seeking to conduct early feasibility studies in Colombia or other South American countries.
Want to learn more about this success story? Hear directly from Bill Niland as he shares his experience working with bioaccess® and why Colombia is becoming a prime destination for medical innovation.
